Home / Biosimilars / News

News

Hospira starts phase III programme for biosimilar erythropoietin

Hospira, self-proclaimed leader in injectable generics, announced on 9 January 2012 that the company had enrolled the first patient in its phase III programme in the US for its biosimilar erythropoietin (EPO).

First biosimilar G-CSF in Japan

Mochida Pharmaceuticals (Mochida) and development partner Fuji Pharma announced on 26 December 2011 that they had filed respective applications for the first biosimilar granulocyte colony-stimulating factor (G-CSF) in Japan.

Samsung makes biosimilars deal with Biogen Idec

Korean electronics giant Samsung announced on 6 December 2011 that it had entered into a biosimilars joint venture with US biotechnology company Biogen Idec (Biogen).

Indian Transgene sells biosimilar to German TSS Export

India-based biotech company Transgene Biotek Limited (Transgene) announced on 24 November 2011 the sale of technology for biosimilar recombinant human erythropoietin (rh-EPO) to TSS Export GmbH FZE, part of the Germany-based TSS group, for US$5 million (Indian Rupees 260 million).

National Psoriasis Foundation declares biosimilar stance

One of the leading psoriasis patient associations in the US, the National Psoriasis Foundation, has publically declared its stance on biosimilars. In an open letter to FDA, the Foundation issued a statement on the implementation of the Biologics Price Competition and Innovation (BPCI) Act of 2009 [1].

Fujifilm and Kyowa Hakko Kirin in biosimilars joint venture

Japanese Fujifilm Corporation announced on 16 November 2011 that it is once again making an agreement in the biosimilars field, this time with biotech firm Kyowa Hakko Kirin, Tokyo, Japan.

New Amgen Enbrel patent could block biosimilars until 2028

Amgen announced on 22 November 2011 that it had been granted a new US patent on its blockbuster drug Enbrel (etanercept).

Acino grabs Cephalon’s Middle East and African business

Switzerland-based generics company Acino Pharma announced on 14 October 2011 that it had agreed to buy biopharmaceutical company Cephalon ’s combined Middle East and African business in a transaction worth approximately Euros 80 million.

Natco snaps up biosimilars: signing deal with Mabxience

Indian generic drugmaker Natco Pharma announced that it had entered into an exclusive agreement with Mabxience, the biosimilar division of Swiss firm Chemo Sa Lugano, on 19 September 2011.

Battle rages over anti-thrombotic medicine

Sandoz/Momenta are ahead again in the fight for the lucrative anticoagulants market in the US. According to IMS Health data enoxaparin sodium injection is the best-selling hospital medicine in the US, and has been described as the ‘gold standard’ for anti-thrombotic treatments. Lovenox, sanofi-aventis’ reference product, recorded US sales of US$2.7 billion in 2009 and has been used to treat an estimated 200 million patients worldwide since it was launched.

Generics News Research General

more

Biosimilars News Research General

more